We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

125 hedge funds and large institutions have $912M invested in Verve Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

307% more call options, than puts

Call options by funds: $1.98M | Put options by funds: $485K

24% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 34

11% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 19

2% more funds holding

Funds holding: 123 → 125 (+2)

0.67% more ownership

Funds ownership: 101.68% → 102.34% (+0.67%)

25% less capital invested

Capital invested by funds: $1.21B → $912M (-$300M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
125
Holders Change
+2
Holders Change %
+1.63%
% of All Funds
1.99%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
21
Increased
42
Reduced
34
Closed
19
Calls
$1.98M
Puts
$485K
Net Calls
+$1.49M
Net Calls Change
-$6.36M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$7.6M
2
NAMA
Nikko Asset Management Americas
New York
+$7.24M
3
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$7.24M
4
Citigroup
Citigroup
New York
+$6.43M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$6.35M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$22M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$13.4M
3
GPP
Great Point Partners
Connecticut
-$5.8M
4
APM
Avidity Partners Management
Texas
-$4.18M
5
CC
Casdin Capital
New York
-$3.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
Woodline Partners
California
$5.57M +$200K +10,189 +3%
Bank of America
27
Bank of America
North Carolina
$5.55M -$405K -20,687 -5%
CAM
28
Cormorant Asset Management
Massachusetts
$5.05M – – –
HRCM
29
Hood River Capital Management
Florida
$4.97M +$183K +9,361 +3%
Charles Schwab
30
Charles Schwab
California
$4.65M +$33.7K +1,723 +0.5%
AG
31
Artal Group
Luxembourg
$4.33M – – –
JFG
32
Jefferies Financial Group
New York
$3.85M -$169K -8,642 -3%
ECM
33
ExodusPoint Capital Management
New York
$3.8M +$3.84M +196,276 +291%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$3.79M -$2.15M -109,643 -29%
Goldman Sachs
35
Goldman Sachs
New York
$3.79M -$2.57M -131,291 -33%
GW
36
GW & Wade
Massachusetts
$3.74M -$215 -11 -0%
Morgan Stanley
37
Morgan Stanley
New York
$3.47M +$2.82M +143,878 +148%
PHS
38
PFM Health Sciences
California
$2.68M -$611K -31,215 -14%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$2.47M -$63.5K -3,243 -2%
Mirae Asset Global Investments
40
Mirae Asset Global Investments
South Korea
$2.44M +$238K +12,165 +8%
CSS
41
Cubist Systematic Strategies
Connecticut
$2.42M +$2.17M +111,004 +194%
N
42
Nuveen
North Carolina
$2.32M -$543K -27,750 -15%
Jane Street
43
Jane Street
New York
$2.23M +$2.76M +140,774 +1,019%
TC
44
TwinBeech Capital
New York
$2.07M +$1.57M +80,177 +127%
Two Sigma Investments
45
Two Sigma Investments
New York
$2.04M +$2.78M +141,756 New
Squarepoint
46
Squarepoint
New York
$1.81M +$1.62M +82,945 +195%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$1.71M +$882K +45,019 +61%
Barclays
48
Barclays
United Kingdom
$1.57M -$1.83M -93,543 -46%
UBS Group
49
UBS Group
Switzerland
$1.31M -$2.99M -152,939 -63%
AllianceBernstein
50
AllianceBernstein
Tennessee
$1.14M -$1.96K -100 -0.1%
1
2
3 4 5

VERV Hedge Fund Activity: Q1 2023 in Review

125 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q1 2023, worth a combined $912M — down 25% from $1.21B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new VERV positions and 19 closed out — a net gain of 2 holders — while 42 added to existing stakes and 34 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $7.6M. The largest seller was State Street, cutting an estimated $22M.

  • 125 institutional investors held Verve Therapeutics (VERV) as of Q1 2023, up from 123 in Q4 2022.
  • Funds reported $912M of Verve Therapeutics stock for Q1 2023, down 25% quarter-over-quarter.
  • 21 funds opened new Verve Therapeutics positions in Q1 2023 and 19 closed out, a net change of +2 holders.
  • The largest Verve Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $7.6M added.
  • The largest Verve Therapeutics seller in Q1 2023 was State Street, an estimated $22M sold.

Based on aggregated 13F filings for Q1 2023.